Direct interactions between the genes that regulate development and those which regulate the cell cycle would provide a mechanism by which numerous biological events could be better understood. We have identified a direct role for PAX5 in the control of p53 transcription. In primary human diffuse astrocytomas, PAX5 expression inversely correlated with p53 expression. The human p53 gene harbours a PAX binding site within its untranslated first exon that is conserved throughout evolution. PAX5 and its paralogues PAX2 and PAX8 are capable of inhibiting both the p53 promoter and transactivation of a p53-responsive reporter in cell culture. Mutation of the identified binding site eliminates PAX protein binding in vitro and renders the promoter inactive in cells. These data suggest that PAX proteins might regulate p53 expression during development and propose a novel alternative mechanism for tumour initiation or progression, by which loss of p53 function occurs at the transcriptional level.
Introduction
One aim of genes that are involved in controlling developmental processes is to influence the cell cycle in time and space. By manipulating the cell cycle, developmental regulatory genes direct cellular growth and differentiation, and thus permit embryogenesis to proceed in an exquisitely controlled manner. Such genes are also likely candidates for involvement in oncogenesis, owing to their effects on cell growth.
Pax genes encode nuclear transcription factors which have been implicated in the control of mammalian development (Gruss and Walther, 1992; Chalepakis et al., 1993; Stuart et al., 1994) . Thus far, nine mammalian Pax genes have been identified (Stapelton et al., 1993) . All PAX proteins contain a conserved DNA binding motif termed the paired box. In addition, some contain a full homeodomain (PAX3, 7,4 and 6) whereas others contain a partial homeodomain (PAX2, 5 and 8) and yet others none at all (PAX1 and 9). Mutations within Pax genes have been demonstrated to be involved in three mouse developmental mutants and two corresponding human syndromes (Chalepakis et al., 1993; Stuart etal., 1994) . During development ofthe central nervous system, PAX2, 5 and 8 are most highly expressed in the ventricular zone. In addition, PAX5 is an important regulator of B cell development and its mutation arrests B cells at an early stage of development (Barberis et al., 1990; Adams et al., 1992 ; Urbanek et al., 1994) . Murine Pax genes have been shown to act as proto-oncogenes as they are able to transform cells in culture which subsequently form tumours in nude mice (Maulbecker and Gruss, 1993) . Recently, a number of human Pax genes have been implicated in various types ofcancer-Pax5 in astrocytomas (Stuart et al., 1995) , Pax2 and 8 in Wilms' tumour (Dressler and Douglass, 1992; Poleev et al., 1992) and Pax3 and 7 in rhabdomyosarcoma Galili et al., 1993; Shapiro et al., 1993; Davis et al., 1994) .
The p53 tumour suppressor gene encodes a nuclear transcription factor and is the most commonly mutated gene in human cancer thus far identified (Oren, 1992; Donehower and Bradley, 1993) . These mutations commonly occur in its DNA binding domain, rendering it unable to transactivate its target genes (Prives, 1994 ). p53 appears to control the cell cycle by arresting cells in late GI phase by activating downstream target genes, notably WAFJ (El-Deiry et al., 1993) . In addition to its role in the cell cycle, p53 has been demonstrated to mediate apoptosis in a variety of cell types (Oren, 1994) . Studies involving the control of expression of p53 itself have so far provided only limited insight into the transcriptional regulation of the p53 gene Deffie et al., 1993) . In contrast, the p53 protein appears to be regulated exquisitely by a variety of mechanisms which affect its quantity as well as its function (Momand et al., 1992; Oliner et al., 1992; Zauberman et al., 1993) and also by viral proteins Levine, 1993a,b) .
The role of p53 in developmental processes has not been studied extensively, although it appears to undergo temporal and spatial changes in expression during prenatal development (Rogel et al., 1985; Schmid et al., 1991) .
In this report, we demonstrate that one class of PAX proteins is capable of inhibiting human p53 expression by direct DNA binding of the PAX protein to a sequence in the 5' region of the p53 gene. In addition, mutational analysis ofthe PAX binding site revealed that it is absolutely required for basal promoter activity, suggesting that PAX proteins may bind to this site and physically impede an as yet unidentified positive regulatory factor transactivating the promoter. We discuss potential implications of these results for oncogenesis and we present a model for PAX-mediated regulation of the cell cycle and of specific differentiation events during embryonic development.
Results

PAX5 expression in human astrocytomas
We have previously demonstrated a positive correlation between PAX5 expression and the level of malignancy in p53 inhibition by PAX AA6 -A G^r.-' 0.
-nI I * ..14--.nIII- Fig. 1 . PAX5 mRNA expression inversely correlates with mutant p53 protein in primary human astrocytomas. In the left panel, no PAX5 expression was detected in a medium grade (WHO grade III) anaplastic astrocytoma (B) and p53 was abundantly expressed (C). In the right panel, a representative glioblastoma multiforme (WHO grade IV), PAX5 was focally expressed (E) and p53 was not expressed (arrow) (F). Tumour identification numbers in the top left of each phase contrast panel correspond to those previously described (Stuart etal., 1995) .
human astrocytic tumours (Stuart et al., 1995 Figure 2 shows that PAX5 had a pronounced inhibitory effect on p53-dependent reporter activity. A comparable inhibitory effect was also exerted by PAX2 and PAX8, both of which share substantial sequence and structural similarity with PAX5 (Stuart et al., 1994 (Tuck and Crawford, 1989) , exon 1 and a large (10 kb) intron which harbours a strong but unrelated promoter in its first 1.2 kb (Reisman et al., 1988) . The p53 promoter, exon 1 and 1.2 kb 3' of intron 1 were analysed for PAX binding sites by electrophoretic mobility shift assays (EMSAs). A single PAX binding site was identified which resides at the 3' end of exon 1 between nucleotides +166 and +216 [+1 refers to the transcriptional start site, as previously defined (Tuck and Crawford, 1989) ]. This binding site (Figures 3B and 4A) contains the PAX core motif GTYMC as well as the CA dinucleotide previously identified in PAX5 binding sites (Czerny et al., 1993) . Figure 3A shows binding of various PAX proteins to this sequence. PAX2, 5 and 8 bound most efficiently to this site, PAXI and 6 exhibited relatively weaker binding, whereas PAX3 did not bind at all. The presence of a partial homeodomain in PAX2, 5 and 8 may be important for efficient binding, as two deletion mutants, PaxA3 (similar to the murine splotch Pax3) and PaxA6 (similar to the small eye Pax6), which contain only the paired domain, display greater binding to this sequence than their wild-type counterparts which contain a full homeodomain. The sequence of the PAX binding site identified in the EMSA is highly conserved between mouse, rat and man ( Figure 3B ), supporting the functional significance of this site.
To characterize the PAX binding site further, we subjected it to mutational analysis ( Figure 4A ). Point mutation of the C within the CA dinucleotide did not affect binding; nor did mutation 4 (data not shown). By contrast, mutations 2 and 3, introduced within the PAX core motif, significantly reduced binding of all PAX proteins ( Figure 4B ). PAX2, 5 and 8 inhibit the activity of the isolated p53 promoter in cell culture PAX proteins bind to a sequence within the first exon of the human p53 gene, and PAX2, 5 and 8 are capable of strongly decreasing p53 protein function in cell culture.
These observations proposed a mechanism whereby PAX proteins may exert their inhibitory effect on p53 function by directly repressing the transcription of the p53 gene itself. We therefore constructed a reporter plasmid, pS3LUC, which contains a 490 bp genomic fragment comprising the p53 promoter and exon 1, in front of the firefly luciferase gene ( (1985) . In the mouse and rat, the GTCAC motif is located on the sense strand, whereas the human GTCAC motif is located on the antisense strand. Numbers refer to the nucleotide position according to Tuck and Crawford (1989) .
sion plasmids into primary rat embryo fibroblasts and reporter activity was assayed ( Figure 5A , lower panel Point mutation of the p53 promoter abolished transcriptional activity To test whether the PAX binding site is an absolute requirement for transcriptional inhibition, we generated pS3mutLUC (Figure SB, upper panel) . This reporter construct is identical to the wild-type p53 promoter-luciferase construct, with the exception of a single point mutation in the PAX binding site core motif previously found to virtually eliminate PAX binding ( Figure 4A) . Surprisingly, all promoter activity was totally ablated when this construct was transfected into a number of cell types, including NIH 3T3 and primary rat embryo fibroblasts ( Figure lower panel). We conclude that the PAX binding site is also required for basal promoter activity. In support of this conclusion, deletion analysis of the p53 promoter and exon 1, from either the 5' or 3' end, demonstrated that only the most 3' 85 bp of exon 1 were essential for promoter activity (Tuck and Crawford, 1989) . Furthermore, the sequence directly 3' to the PAX pentanucleotide core binding sequence is highly conserved between mouse, rat and human (Bienz-Tadmor et al., 1985) . This sequence, CACGCTTCCC, shows high homology to the consensus binding sequence for TFII-I, a regulator of basal transcription (Roy et al., 1991) . Recently, mutation of the murine PaxS gene has been described (Urbanek et al., 1994) . The homozygous mice display a number of phenotypes which include a complete block in early B cell differentiation. B cell differentiation proceeds along a well documented path from stem cells to the immunoglobulin-secreting plasma cells (for reviews, see Rolink and Melchers, 1991; Kantor and Herzenberg, 1993; Hagman and Grosschedl, 1994) . PAX5 is expressed during the early stages of B cell differentiation, i.e. up to the mature B cell stage and, in the later blast and plasma cell stages, PAXS expression is no longer detectable (Barberis et al., 1990; Adams et al., 1992) . However, in PaxS mutant mice, B cell differentiation is arrested in the early pro-B cell stage, with the cells displaying CD45 expression (which is normally lost during later differentiation stages) and the cells being morphologically different from the corresponding wild-type cells which undergo normal differentiation (Urbanek et al., 1994) . One feature of B cell differentiation is a selection at the mature B cell/blast stage prior to plasma cell genesis. This selective period determines which cells will progress through to plasma cells and which will undergo apoptosis (Rolink and Melchers, 1991) . The mechanisms which underlie the apoptotic death of B cells are partly understood at present. bcl-2 prevents apoptosis selectively in B cells (Vaux et al., 1988; McDonnell et al., 1989; Henderson et al., 1991) and the bax gene encodes a protein which has opposite physiological functions (Miyashita and Reed, 1995) . Both of these genes are potentially controlled by p53 (Miyashita et al., 1994a,b; Miyashita and Reed, 1995) . Therefore, it is conceivable that p53 is involved in B cell apoptosis. PAX5 expression would inhibit p53, the consequences of which would be an inhibition of BAX and continued expression of Bcl-2. Such a scenario would agree both with our observations and those of the Pax5 mutant mice. We envisage that expression of PAX5 early in pro-B cell differentiation is required to inhibit p53 expression, leading to a rapid growth and partial differentiation phase during which complete differentiation is not permitted and, probably more importantly, the cellular decisions concerning apoptosis are prevented. Once PAXS expression is reduced, p53 expression commences and the final stages of differentiation occur. In the absence of PAX5, the myriad of molecular mechanisms which it controls are deregulated and, in particular, p53 is active in the early phases during which it would otherwise not be active.
Implications for cancer Inactivation of p53 is an extremely common event in human cancer (Levine et al., 1991; Fults et al., 1992) . However, with the exception of functional inactivation of the p53 protein by either viral proteins (Ludlow, 1993) or the product of the MDM2 gene (Momand et al., 1992; Oliner et al., 1992) , all previously reported examples of p53 inactivation in human tumours have been due to mutations within the p53 gene or gross chromosomal rearrangements involving the p53 locus. The effect of mutating p53 has been studied widely and results in compromised sequence-specific DNA binding and transcriptional activity (Oren, 1992; Donehower and Bradley, 1993) . Thus, the commonly encountered p53 mutations eliminate the normal tumour suppressor function of p53 by producing a functionally deficient protein.
Our results indicate the existence of a novel mechanism for loss of p53 activity, namely the inhibition of p53 gene expression by PAX proteins. The constitutive expression of PAX5 or a related protein would thus bypass the need for p53 mutation to abrogate p53-mediated processes. Cancer is a multi-step process, which requires the cumulative effects altering both positive and negative regulators of cell proliferation and cell survival (Nowell, 1986; Vogelstein and Kinzler, 1993) . Abrogation of p53 transcription by PAX may serve as an important factor in this multi-step process. In addition, it is conceivable that inappropriate PAX expression may contribute to tumorigenesis by activating specific target genes, as well as by inactivating other inhibitory genes in addition to p53. Progression of a tumour to a higher state of malignancy is one of the most important aspects of cancer. Many tumours start as low malignancy neoplasms which, even after conventional treatment, progress to higher forms of malignancy. These often harbour metastatic potential which grossly alters patient prognosis. Our initial observation demonstrated that PAXS is overexpressed in highly malignant glioblastoma multiform tumours, whereas tumours of lower malignancy (anaplastic astrocytomas, astrocytomas) did not express significant levels of PAXS (Stuart et al., 1995) . We surmised that PAX5 may play a role in progression of the tumour, and its ability to inhibit p53 concurs with this. It is of note that if a mutant form of p53 was already present in the tumour cell and the promoter was not mutated, then PAX5 would also inhibit expression of this mutant p53. However, it is conceivable that p53 is only one of a set of PAX5 target genes whose activation or inhibition may combine to provide the cancer cell with a positive growth advantage. Thus, even in cells which have already lost wild-type p53 function owing to prior p53 gene alterations, the activation of PAXS will probably have a net selective advantage.
Another tumour which may potentially relate to these observations is Wilms' tumour (nephroblastoma), a pediatric renal tumour affecting 1 in 10 000 children (for review, see Hastie, 1994 (Dressler and D,ouglass, 1992; Eccles et al., 1992; Poleev et al., 1992) . The status of p53 has not been studied widely in Wilms' tumour, although it has been reported that in vitro the Wilms' tumour suppressor gene product WT1 can form a transcriptionally active complex with wild-type p53 and that p53 is mutated in a small subset of Wilms' tumours (Hastie, 1994) . In view of the negative effects of PAX2 and 8 on p53, comparable with those of PAX5, it is tempting to speculate that the aberrant expression of these proteins in Wilms' tumour may also contribute to malignancy by compromising p53 function.
In conclusion, we have demonstrated a role for regulators of development in directing the cell cycle to allow the proper development of the embryo. In addition, reactivation of these pathways later in life may constitute an important novel mechanism for tumorigenesis in humans.
Materials and methods
Recombinant plasmids PAX cDNAs were cloned into pCMV expression plasmids and have been described previously (Maulbecker and Gruss, 1993) . RGC-CAT contains multiple copies of a p53 binding sequence located near the ribosomal gene cluster in front of the CAT gene (Kern et al., 1991 Preparation of whole cell extracts and electrophoretic mobility shift assays COS-7 cell extracts were prepared and EMSA performed as previously described (Chalepakis et al., 1991 
